Skip to content
Screener

United Therapeutics UTHR Cash And Cash Equivalents At Carrying Value

Cash And Cash Equivalents At Carrying Value at other companies

Cal-Maine Foods logo
Cal-Maine FoodsCALM
$107.22M-78.5%
NewAmsterdam Pharma Company logo
NewAmsterdam Pharma CompanyNAMS
$424.15M-24.8%
SharkNinja logo
SharkNinjaSN
$779.83M—
TETRA Technologies logo
TETRA TechnologiesTTI
$154.58M+125%
Taboola.com Ltd. logo
Taboola.com Ltd.TBLA
$133.05M+15.5%
United Therapeutics logo
United TherapeuticsUTHR
$1.8B+13.2%

Other financials

Income statement

See full
Revenue$783.3M-1.9%
Gross profit$683.8M-3.8%
Operating income$330.8M-9.2%
Net income$333.0M+7.6%
EPS (diluted)$7.27+13.4%

Balance sheet

See full
Cash & equivalents$1.8B+13.2%
Total debt$12.2M—
Total equity$6.4B-10.8%
Total assets$7.2B-8.7%

Cash flow

See full
Operating cash flow$313.6M+63.6%
CapEx$108.0M+73.6%
Free cash flow$205.6M+58.8%

Valuation

See full
Market cap$22.03B+61.1%
P/E16.8×+5.8×
P/S7×+2.5×

Profitability

See full
Gross margin86.1%-2.8pp
Operating margin44.4%-2.6pp
Net margin41.6%+1.2pp
FCF margin34.6%-0.1pp

Returns & leverage

See full
Return on equity19.3%0.0pp
Debt / equity0×—
Current ratio5.7×-1.5×

Where this comes from

Reported directly by United Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The source filing: United Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →

Filed
Aug 5, 2026, 6:31 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001082554-26-000027

FAQ

What is United Therapeutics's cash and cash equivalents at carrying value?
United Therapeutics (UTHR) reported cash and cash equivalents at carrying value of $1.8B in Q2 2026.
How has United Therapeutics's cash and cash equivalents at carrying value changed year-over-year?
United Therapeutics's cash and cash equivalents at carrying value increased by 13.2% year-over-year, from $1.59B to $1.8B.
What is the long-term trend for United Therapeutics's cash and cash equivalents at carrying value?
Over 5 years (2020 to 2025), United Therapeutics's cash and cash equivalents at carrying value has grown at a 16.1% compound annual growth rate (CAGR), from $738.7M to $1.56B.
What does cash and cash equivalents at carrying value mean?
Cash And Cash Equivalents At Carrying Value as reported by United Therapeutics Corp.

Ask your AI about United Therapeutics's cash and cash equivalents at carrying value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude